Screener
Ocular Therapeutix OCUL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $666,699 | $737,060 |
| Accounts receivable, net | 24,347 | 30,650 |
| Inventory | 3,737 | 3,564 |
| Prepaid expenses and other current assets | 11,212 | 10,855 |
| Total current assets | 705,995 | 782,129 |
| Property and equipment, net | 18,425 | 19,676 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's cash & equivalents?
- Ocular Therapeutix (OCUL) reported cash & equivalents of $666.7M in Q1 2026.
- How has Ocular Therapeutix's cash & equivalents changed year-over-year?
- Ocular Therapeutix's cash & equivalents increased by 90.7% year-over-year, from $349.68M to $666.7M.
- What is the long-term trend for Ocular Therapeutix's cash & equivalents?
- Over 5 years (2020 to 2025), Ocular Therapeutix's cash & equivalents has grown at a 26.4% compound annual growth rate (CAGR), from $228.06M to $737.06M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Ocular Therapeutix's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude